CA2936548C - The use of a benzoate containing composition in urea cycle disorders and neurodegenerative disorders - Google Patents

The use of a benzoate containing composition in urea cycle disorders and neurodegenerative disorders Download PDF

Info

Publication number
CA2936548C
CA2936548C CA2936548A CA2936548A CA2936548C CA 2936548 C CA2936548 C CA 2936548C CA 2936548 A CA2936548 A CA 2936548A CA 2936548 A CA2936548 A CA 2936548A CA 2936548 C CA2936548 C CA 2936548C
Authority
CA
Canada
Prior art keywords
mice
pharmaceutical composition
gtb
glyceryl
eae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2936548A
Other languages
English (en)
French (fr)
Other versions
CA2936548A1 (en
Inventor
Kalipada PAHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rush University Medical Center
Original Assignee
Rush University Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rush University Medical Center filed Critical Rush University Medical Center
Publication of CA2936548A1 publication Critical patent/CA2936548A1/en
Application granted granted Critical
Publication of CA2936548C publication Critical patent/CA2936548C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2936548A 2014-01-17 2015-01-16 The use of a benzoate containing composition in urea cycle disorders and neurodegenerative disorders Active CA2936548C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461928622P 2014-01-17 2014-01-17
US61/928,622 2014-01-17
PCT/US2015/011798 WO2015109215A1 (en) 2014-01-17 2015-01-16 The use of a benzoate containing composition in urea cycle disorders and neurodegenerativre disordrs

Publications (2)

Publication Number Publication Date
CA2936548A1 CA2936548A1 (en) 2015-07-23
CA2936548C true CA2936548C (en) 2022-08-30

Family

ID=53543490

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2936548A Active CA2936548C (en) 2014-01-17 2015-01-16 The use of a benzoate containing composition in urea cycle disorders and neurodegenerative disorders

Country Status (16)

Country Link
US (1) US9968582B2 (https=)
EP (1) EP3094616B1 (https=)
JP (2) JP6836905B2 (https=)
CA (1) CA2936548C (https=)
CY (1) CY1124115T1 (https=)
DK (1) DK3094616T3 (https=)
ES (1) ES2853974T3 (https=)
HR (1) HRP20210361T1 (https=)
HU (1) HUE053671T2 (https=)
LT (1) LT3094616T (https=)
PL (1) PL3094616T3 (https=)
PT (1) PT3094616T (https=)
RS (1) RS61611B1 (https=)
SI (1) SI3094616T1 (https=)
SM (1) SMT202100074T1 (https=)
WO (1) WO2015109215A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202090666A1 (ru) * 2017-10-06 2020-08-05 Раш Юниверсити Медикал Сентер Применение содержащей бензоат композиции для лечения глициновой энцефалопатии
JP7034314B2 (ja) * 2017-11-22 2022-03-11 潔欣 林 うつ病を予防または治療するための安息香酸またはその塩および誘導体
US12478598B2 (en) 2019-02-25 2025-11-25 Rush University Medical Center Compositions including cinnamic acid and methods of use thereof
CN114502154A (zh) * 2019-07-16 2022-05-13 拉什大学医学中心 含苯甲酸酯的组合物治疗神经退行性疾病的用途
CN116390761A (zh) * 2020-10-28 2023-07-04 拉什大学医学中心 肉桂酸苄酯组合物在治疗甘氨酸脑病和尿素循环障碍中的应用
CA3205005A1 (en) * 2020-12-16 2022-06-23 Rush University Medical Center Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders
JP2025503457A (ja) * 2021-12-16 2025-02-04 ザ ユナイテッド ステイツ ガバメント アズ リプレゼンティド バイ ザ デパートメント オブ ヴェテランズ アフェアーズ 神経系損傷及び障害の治療のための安息香酸塩

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) * 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
WO2008083226A2 (en) 2006-12-28 2008-07-10 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate

Also Published As

Publication number Publication date
CY1124115T1 (el) 2022-05-27
EP3094616B1 (en) 2020-12-23
US9968582B2 (en) 2018-05-15
ES2853974T3 (es) 2021-09-20
SI3094616T1 (sl) 2021-07-30
JP2017505811A (ja) 2017-02-23
SMT202100074T1 (it) 2021-05-07
CA2936548A1 (en) 2015-07-23
US20160331714A1 (en) 2016-11-17
EP3094616A1 (en) 2016-11-23
HRP20210361T1 (hr) 2021-04-16
RS61611B1 (sr) 2021-04-29
JP2020037558A (ja) 2020-03-12
HUE053671T2 (hu) 2021-07-28
LT3094616T (lt) 2021-04-12
PL3094616T3 (pl) 2021-05-31
WO2015109215A1 (en) 2015-07-23
JP6836905B2 (ja) 2021-03-03
EP3094616A4 (en) 2017-08-23
PT3094616T (pt) 2021-03-03
DK3094616T3 (da) 2021-02-15

Similar Documents

Publication Publication Date Title
CA2936548C (en) The use of a benzoate containing composition in urea cycle disorders and neurodegenerative disorders
Cummings et al. Alzheimer’s disease: novel targets and investigational drugs for disease modification
Wang et al. Angelica sinensis polysaccharide attenuates CCl4-induced liver fibrosis via the IL-22/STAT3 pathway
Mondal et al. Cinnamon ameliorates experimental allergic encephalomyelitis in mice via regulatory T cells: implications for multiple sclerosis therapy
US12478598B2 (en) Compositions including cinnamic acid and methods of use thereof
AU2022200277A1 (en) The use of a benzoate containing composition to treat glycine encephalopathy
RU2336870C2 (ru) Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта
Yang et al. Irbesartan suppresses lipopolysaccharide (LPS)-induced blood–brain barrier (BBB) dysfunction by inhibiting the activation of MLCK/MLC
JP2023532880A (ja) カンナビジオールによる脆弱ｘ症候群の処置
CN104519884A (zh) 轻度认知障碍的预防和/或治疗剂
CN116390761A (zh) 肉桂酸苄酯组合物在治疗甘氨酸脑病和尿素循环障碍中的应用
CN104411308B (zh) 通过给予某些合成化合物治疗阿尔茨海默病的方法
CN118903111A (zh) 吲哚在制备治疗肝纤维化药物中的用途
CN104173361A (zh) 宝霍苷i在制备防治阿尔茨海默病药物中的用途
CN120514742A (zh) 一种预防或治疗阿尔兹海默症的益生菌剂及其应用
CN116723870A (zh) 球形细胞脑白质营养不良症或克拉伯病的改良治疗
CN115429799A (zh) Magl抑制剂在制备预防或治疗肝炎药物中的用途
JP7796412B2 (ja) 血液脳脊髄関門保護剤
CN112516160A (zh) 一种医药组合物及其医药用途
RU2805061C2 (ru) Лечение демиелинизирующих заболеваний
CN121265607A (zh) 防治脑海绵状血管畸形病变的药物及其应用
Croasdell Alzheimer’s Association International Conference 2020
Croasdell Alzheimer
CN121221648A (zh) 脆弱拟杆菌在制取治疗视神经损害的药械或食品中的应用
CN114984034A (zh) 一种寡糖类化合物的应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200115

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250110

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250110